By Fineline Cube 
UK-based GlaxoSmithKline (GSK; NYSE: GSK) released its Q2 and H1 2025 financial results. Q2 sales reached GBP 7.99 billion (USD 10.66 billion), reflecting a 6% year-on-year (YOY) growth in constant currency terms. H1 sales were up 5% YOY to GBP 15.5 billion (USD 20.7 billion).
Q2 Performance by Segment
- Specialty Medicine: Sales increased by 15% YOY to GBP 3.3 billion.
- Vaccines: Sales grew by 9% to GBP 2.1 billion.
- General Medicines: Sales decreased by 6% to GBP 2.6 billion.
Key Product Highlights
- HIV Treatments: Showed strong growth of +12% to GBP 1.88 billion (USD 2.5 billion), driven by long-acting injectables (LAIs).
- Nucala (Mepolizumab): Q2 sales rose 7% to GBP 498 million (USD 665 million), despite pricing pressure in the U.S. due to Medicare reforms, with stronger growth in Europe and international markets.
- Benlysta (Belimumab): Sales increased by 13% to GBP 451 million (USD 602 million).
- Oncology Sales: Rose by 42% to GBP 484 million (USD 646 million), driven by Jemperli (dostarlimab), Zejula (niraparib), and Ojjaara/Omjjara (momelotinib). Jemperli sales grew by 91% to GBP 196 million (USD 262 million).
- Vaccines: Shingrix sales reached GBP 853 million (USD 1,138 million, +6%); Meningitis vaccines generated GBP 379 million (USD 506 million, +22%); RSV vaccine Arexvy grew by 13% to GBP 66 million (USD 88 million).
Hengrui Partnership
GSK recently announced a significant partnership with China’s Hengrui Medicine. The deal involves an upfront payment of USD 500 million and covers up to 12 innovative medicines, with a focus on GSK’s Respiratory, Immunology & Inflammation (RI&I) and Oncology businesses. The first selected candidate is a potential best-in-class PDE3/4 inhibitor (HRS-9821) for COPD treatment. GSK will hold all development and commercial rights outside the Greater China market.-Fineline Info & Tech